MichaelMullaneMD

PubMed

• 3 citations
  Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance.
  Mary K Walters, Andrew T Ackerman, James L Weese, Antony Ruggeri, Michael P Mullane, Alicia Hunt, Amanda Wilson, Brenda L Ramczyk, Michael A Thompson> ;JCO Precision Oncology. 2022 Oct 1
• 82 citations
  Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
  Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Ch...> ;Blood. 2022 Jul 14
• 6 citations
  Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.
  Michael A Thompson, Sigrun Hallmeyer, Veronica E Fitzpatrick, Yunqi Liao, Michael P Mullane, Stephen C Medlin, Kenneth Copeland, James L Weese> ;Journal of Patient-Centered Research and Reviews. 2022 Jan 1
• 16 citations
  Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.
  Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta, Susan O'Brien, Jacqueline C. Barrientos, Jose F. Leis, Cong Ch...> ;Blood. 2021 Aug 18
• 424 citations
  Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
  Tait D. Shanafelt, Xin V. Wang, Neil E. Kay, Curtis A. Hanson, Susan O'Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong C. Zhang,...> ;The New England Journal of Medicine. 2019 Jul 31
• 7 citations
  Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One.
  Michael A. Thompson, Jennifer J Godden, Deborah Wham, Antony Ruggeri, Michael P Mullane, Amanda Wilson, Shamsuddin Virani, Scott M Weissman, Brenda Ramczyk, Pamela Van...> ;Journal of Patient-Centered Research and Reviews. 2019 Jan 28
• 5 citations
  Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
  Aaron S. Mansfield, Ben Ho Park, Michael P Mullane> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2018 May 23
• 19 citations
  Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series.
  Tobias Else, Antonio M. Lerario, Jessica Everett, Lori Haymon, Deborah Wham, Michael P Mullane, Tremika Le Shan Wilson, Irene Rainville, Huma Q. Rana, Andrew J. Worth,...> ;European Journal of Endocrinology. 2017 Aug 17
• 1 citations
  Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response
  Michael A. Thompson, Martin K. Oaks, Maharaj Singh, Karen M Michel, Michael P Mullane, Husam S Tarawneh, Angi Kraut, Kayla J Hamm> ;Journal of Patient-Centered Research and Reviews. 2017 Jan 1
• 9 citations
  CD8-positive primary cutaneous anaplastic large T-cell lymphoma (PCALCL): case report and review of this unusual variant of PCALCL.
  Jose A. Plaza, Pablo F. Ortega, James Lynott, Michael Mullane, Steve Kroft, Horatiu Olteanu> ;The American Journal of Dermatopathology. 2010 Jul 1
• Join now to see all

Abstracts/Posters

• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Michael P. Mullane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Discussing Test Results: Understanding Actionable and Nonactionable Mutations 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018